How orphan designated drugs private equity performed in the pharmaceutical industry in Q2 2023

In value terms, orphan designated drugs-related deal activity increased by 2248% in Q2 2023 compared with the previous quarter’s total of $22.8m and fell by 56% as compared to Q2 2022. Related deal volume increased by 133% in Q2 2023 versus the previous quarter and was 42% lower than in Q2 2022.

The top-ranked legal advisors supporting these private equity deals in Q2 2023 were Goodwin Procter; Latham & Watkins; Lefevre Pelletier & associes, Avocats with 1, 1, 1 deals respectively.

For further understanding of GlobalData’s New Drug Approvals and Their Contract Manufacture – 2023 Edition buy the report here.

This content was updated on 18 July 2023

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.

Opinion | Medical Debt Is Killing Our Patients

Venkat is an emergency physician and state representative. As an emergency medicine resident in the early 2000s, I cared for a patient in her early

September 17, 2023

Emergency departments prove fertile ground for smoking cessation success

The Cessation of Smoking Trial in the Emergency Department (COSTED) study demonstrates that a brief intervention including e-cigarette starter kits can significantly help smokers in

March 28, 2024

Addex receives $3m to research substance use therapy – Pharmaceutical Technology

Addex also raised $5m in funding for providing a cash runway to achieve development milestones for drug partnerships with Janssen and Indivior. Image Credit: Golden

August 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.